Abiopharma

Identifying Details of New Security-ICL B8-I

Trustee report for BONDS Series 1 for the year 2025, Strauss Lazar

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Bitmine Immersion Technologies gibt erste Dividendenausschüttung und Notierung der Vorzugsaktien der Serie A an der NYSE bekannt

Bitmine Immersion Technologies annonce les premiers dividendes et la cotation au NYSE de ses actions privilégiées de série A

Bitmine Immersion Technologies kondigt initiële dividenden en een NYSE-notering aan voor Series A Preferred Stock

Dormant shares - change in the number of shares

Dormant shares - change in the number of shares

NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with the Schall Law Firm